Description
Created On: 2020-07-15
Record Count: 6
Primary Industries
- Drugs
- Proteins
- Therapeutic
- Diagnostic
- Disease
- Delivery
- Cancer
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 279390
Receptor Associated Protein means the receptor associated protein.
The patents include Compositions & Methods for Modulating BloodBrain Barrier Transport; Delivery of Therapeutic Compounds to the Brain and Other Tissues; Use of Chaperone-Receptor-Associated Protein (RAP) for the Delivery of Therapeutic Compounds to the Brain and Other Tissues; Megalin-Based Delivery of Therapeutic Compounds to the Brain and Other Tissues; and Compositions Comprising Receptor-Associated Protein (RAP) Variants and Uses Thereof.
The trademark is NEUROTRANSâ„¢.
Licensee is an early stage, biotechnology research and development company involved in the development of novel drugs and drug-targeting platform, based on the use of receptor-associated protein.
IPSCIO Record ID: 203509
IPSCIO Record ID: 293999
Licensor agrees to grant Licensee a right of first look at Licensor’s proprietary product(s) for the treatment of Gauchers Disease, to enable Licensee to evaluate its interest in negotiating and obtaining the GCD License (as such term is defined herein), all subject to and in accordance with the terms and conditions set out herein.
The Parties hereby agree to collaborate in the development, and the manufacturing of the Proteins, on the basis of the Platform IP.
Protein(s) each of the two (2) therapeutic proteins as selected by Licensee and agreed upon by Licensor (such agreement not to be unreasonably withheld, conditioned or delayed), expressed in plant cell-expression system outlined in this agreement as might be substituted subject to the terms of this Agreement.
Platform IP shall mean Licensor’s existing and future proprietary recombinant plant culture process and technologies directly related to such process, and improvements thereto, as may be further developed in the course of the collaboration, or otherwise, by or for Licensor, at any time prior to the expiration of fifteen (15) years following the First Commercial Sale of the first Licensed Product. The list of patents and patent applications included under the Platform IP hereto as the Platform Patents.
6,391,638 – Cell/tissue culturing device and method
IP shall mean (i) all inventions, materials, compounds, compositions, substances, methods, processes, techniques, know-how, technology, data, information, discoveries and other results of whatsoever nature, and any patents, copyrights, proprietary intellectual or industrial rights directly or indirectly deriving therefrom, as well as provisionals, patent applications (whether pending or not), and patent disclosures together with all reissuances, continuations, continuations in part, revisions, extensions, and reexaminations thereof; (ii) all trademarks, service marks, copyrights, designs, trade styles, logos, trade dress, and corporate names, including all goodwill associated therewith; (iii) any work of authorship, regardless of copyrightability, all compilations, all copyrights; and (iv) all trade secrets, confidential information and proprietary processes.
Plant cell expression system is capable of producing “human like†proteins that maintain the amino acid structure of the desired human protein as well as a very similar, but not identical, glycan, or sugar, structure.
In the biotechnology field, the production or manufacture of recombinant proteins is commonly referred to as the “expression†of such proteins. Recombinant therapeutic proteins are proteins that are produced by different genetically modified organisms following the insertion of the relevant DNA into their genome and are the basis of most biopharmaceutical drugs currently under development.
IPSCIO Record ID: 204347
Licensor shall assign to Licensee all of its right, title, interest, and all goodwill represented therein, in its marks, but only insofar as such right, title, interest, and goodwill pertains to use of the Licensed Product(s) in the Field.
Cholesterol (CHOL) was added to DORI at a molar ratio of DORI/CHOL 7/3 and the lipid formulation used to transfect COS.7
The marks are Superfectin and Turbofectin.
“Licensed Patent(s)†shall mean any patent which may issue from Licensor's U.S. patent application Serial No. 07/511,219, filed April 19, 1990 and any divisions, continuations, continuations-in-part, or reissues thereof or any foreign patents deriving priority therefrom.
IPSCIO Record ID: 291117
— an exclusive license for the Field in the Territory under the Licensed Patents; and
— an exclusive license for the Field to use the Know-How in the Territory; for the sole and exclusive purpose of developing, making, having made, importing, using and selling Licensed Products in the Territory, including the right to grant sublicenses.
Licensed Patents are titled and related to Liposome Compositions and Methods for the Treatment of Atherosclerosis.
— For Improvements, human and veterinary therapeutics, but limited to products that use or include Large Unilammelar Vesicles (LUVS) as a therapeutic agent which are not associated with any other therapeutic agent other than an apoprotein, the Improvements Field;
— For Know-How, human and veterinary therapeutics, but limited to products that use or include Large Unilammelar Vesicles (LUVS) as a therapeutic agent which are not associated with any other therapeutic agent other than an apoprotein, the Know-How Field;
IPSCIO Record ID: 233462
(a) an exclusive, worldwide license, under Licensor Field Patent Rights and Licensor Field Know-How, to make, have made, use, and have used Candidate Genes and Validated Targets within Oncology; such license shall include the right to grant sublicenses on prior notice to Licensor;
(b) an exclusive, worldwide license, under Licensor Field Patent Rights and Licensor Field Know-How to make, have made, import, use, have used, offer to sell and sell Products; such license shall include the right to grant sublicenses on prior notice to Licensor;
(c) an option to obtain exclusive licenses to Non-Program Field Projects;
(d) a right to either negotiate for rights to collaborate on Gene Therapy Drugs, which embody or are discovered or developed using Licensor Field Patent Rights or Licensor Field Know-How, or a co-exclusive right to make, have made, import, use, have used, offer to sell and sell Gene Therapy Drugs, which embody or are discovered or developed using Licensor Field Patent Rights or Licensor Field Know-How;
(e) an option to co-develop and/or co-promote certain Diagnostic Products, for use in the Field and the area of Oncology, which embody or are discovered or developed using Licensor Field Patent Rights or
Licensor Field Know-How; and
(f) a co-exclusive with Licensor, worldwide license, under Licensor Field Patent Rights and Licensor Field Know-How, to make, have made, use, and have used Program Genes Outside of the Field and to make, have made, use, and have used Candidate Genes and Validated Targets outside of Oncology; such license shall include the right to grant sublicenses on prior written notice to Licensor.
Modified Drug means a compound in the Field which, other than through the use of Licensor Field Know-How or Licensor Field Patent Rights, prior to or outside of the Program, was identified by Licensee to have pharmacological properties of relevance -to its development as a therapeutic product in the Field, and was modified through the use of Licensor Field Know: How or Licensor Field Patent Rights to improve its therapeutic properties at any time during the term of the Program or the Licensee Development Program. Modified Drug does not include any Candidate Protein Drug, Peptido Mimetic, Analog Protein Drug, Small Molecule Drug, Gene Therapy Drug or Antisense Drug.
Candidate Protein Drug means a Protein encoded by a Candidate Gene or other Protein, the identification of which other Protein was based upon the identification of a Candidate Gene, and which, in either case, is potentially suitable for development into a therapeutic product.
Analog Protein Drug means a protein or polypeptide which has been modified through a change in its primary structure resulting in a functionally significant change (such as a change in its pharmacokinetic or pharmacodynamic properties) to allow it to become a therapeutic Product demonstrating relevant In Vitro and In Vivo activity. For purposes of this definition, a polypeptide constituting the pharmacologically active fragment of a protein, that has not been modified through a change in its primary structure resulting in a functionally significant change, shall not be considered an Analog Protein Drug.
Peptido Mimetic Drug means a synthetic organic molecule which is a mimetic of, or is designed or developed using medicinal, SAR or combinatorial chemistry techniques to incorporate, key structural features of a Candidate Protein Drug and which is a therapeutic product.
Small Molecule Drug means a small molecule therapeutic product within the Field originating from a screen using a Validated Target, other than a Candidate Protein Drug, an Analog Protein Drug, a Peptido Mimetic Drug, a Modified Drug, a Gene Therapy Drug or an Antisense Drug.
(a) All genes located at chromosome 8p22, including but not limited to loss of prostate cancer hormone-sensitivity, and prostate cancer metastasis to bone;
(b) Mechanisms of drug resistance including but not limited to the association with drug transporters such as P-glycoprotein and MRP, and the mechanism of action of factors that mediate cell death of drug resistant cells or tissues, including but not limited to apoptosis;
(c) Mechanisms of prostatic proliferative conditions including but not limited to the discovery of novel genes implicated in the susceptibility, progression and metastasis of prostate cancer, analysis of prostatic cells and variants of these cells, and malignant tissues;
(d) All cell cycle control mechanisms including but not limited to inhibition of cyclin DI/CDK4 kinase activity; and
(e) All Ras signal transduction mechanisms including but not limited to the inhibition of the Ki-ras pathway, Ras/GTP interaction, Ras/Raf interaction, Raf kinase activity, and Ras/FTase interaction.
Outside of the Field means all human medical indications other than those in the Field and all animal medical indications.
